Triple-Negative Breast Cancer: Current Data and Future Prospects

被引：2
作者：
de Nonneville, A. [1 ]
Goncalves, A. [1 ]
机构：
[1] Aix Marseille Univ, CNRS, INSERM, Inst Paoli Calmettes,Dept Oncol Med,CRCM, F-13009 Marseille, France
来源：
ONCOLOGIE | 2019年 / 21卷 / 1-4期
关键词：
Breast cancer; Triple-negative; BRCA; Immunotherapy; PATHOLOGICAL COMPLETE RESPONSE; RANDOMIZED PHASE-II; BASAL-LIKE; NEOADJUVANT CHEMOTHERAPY; MOLECULAR PORTRAITS; CARBOPLATIN; MULTICENTER; EXPRESSION; CISPLATIN; CETUXIMAB;
D O I：
10.3166/onco-2019-0039
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Triple-negative breast cancer (TNBC), defined by the lack of expression of hormone receptors and HER2 (Human Epidermal growth factor Receptor-2), accounts for 15-20% of breast cancers. However, this definition, which is essentially negative, masks the large biological heterogeneity of this subtype. While chemotherapy is the main established systemic treatment in both early and advanced stages of the disease, the progressive understanding of the molecular components involved in the pathogenesis of TNBC allows innovative therapeutic perspectives. The objective of this review is to describe these potential targets and to explore current and future treatments that will help fighting this cancer with particular aggressive behaviors.
引用
收藏
页码：33 / 39
页数：7
相关论文
共 49 条
  • [1] Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple negative breast cancer (mTNBC).
    Adams, Sylvia
    Diamond, Jennifer Robinson
    Hamilton, Erika Paige
    Pohlmann, Paula Raffin
    Tolaney, Sara M.
    Molinero, Luciana
    He, Xian
    Waterkamp, Daniel
    Funke, Roel Peter
    Powderly, John D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] [Anonymous], CANC RES S
  • [3] Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
    Baselga, Jose
    Gomez, Patricia
    Greil, Richard
    Braga, Sofia
    Climent, Miguel A.
    Wardley, Andrew M.
    Kaufman, Bella
    Stemmer, Salomon M.
    Pego, Antonio
    Chan, Arlene
    Goeminne, Jean-Charles
    Graas, Marie-Pascale
    Kennedy, M. John
    Ciruelos Gil, Eva Maria
    Schneeweiss, Andreas
    Zubel, Angela
    Groos, Jutta
    Melezinkova, Helena
    Awada, Ahmad
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (20) : 2586 - +
  • [4] Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers
    Bertucci, Francois
    Finetti, Pascal
    Cervera, Nathalie
    Charafe-Jauffret, Emmanuelle
    Mamessier, Emilie
    Adelaide, Jose
    Debono, Stephane
    Houvenaeghel, Gilles
    Maraninchi, Dominique
    Viens, Patrice
    Charpin, Colette
    Jacquemier, Jocelyne
    Birnbaum, Daniel
    [J]. CANCER RESEARCH, 2006, 66 (09) : 4636 - 4644
  • [5] A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
    Bonnefoi, H.
    Grellety, T.
    Tredan, O.
    Saghatchian, M.
    Dalenc, F.
    Mailliez, A.
    L'Haridon, T.
    Cottu, P.
    Abadie-Lacourtoisie, S.
    You, B.
    Mousseau, M.
    Dauba, J.
    Del Piano, F.
    Desmoulins, I.
    Coussy, F.
    Madranges, N.
    Grenier, J.
    Bidard, F. C.
    Proudhon, C.
    MacGrogan, G.
    Orsini, C.
    Pulido, M.
    Goncalves, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (05) : 812 - 818
  • [6] Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
    Byrski, T.
    Huzarski, T.
    Dent, R.
    Marczyk, E.
    Jasiowka, M.
    Gronwald, J.
    Jakubowicz, J.
    Cybulski, C.
    Wisniowski, R.
    Godlewski, D.
    Lubinski, J.
    Narod, S. A.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2014, 147 (02) : 401 - 405
  • [7] Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
    Byrski, Tomasz
    Gronwald, Jacek
    Huzarski, Tomasz
    Grzybowska, Ewa
    Budryk, Magdalena
    Stawicka, Malgorzata
    Mierzwa, Tomasz
    Szwiec, Marek
    Wisniowski, Rafal
    Siolek, Monika
    Dent, Rebecca
    Lubinski, Jan
    Narod, Steven
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : 375 - 379
  • [8] 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
    Cardoso, F.
    Costa, A.
    Senkus, E.
    Aapro, M.
    Andre, F.
    Barrios, C. H.
    Bergh, J.
    Bhattacharyya, G.
    Biganzoli, L.
    Cardoso, M. J.
    Carey, L.
    Corneliussen-James, D.
    Curigliano, G.
    Dieras, V.
    El Saghir, N.
    Eniu, A.
    Fallowfield, L.
    Fenech, D.
    Francis, P.
    Gelmon, K.
    Gennari, A.
    Harbeck, N.
    Hudis, C.
    Kaufman, B.
    Krop, I.
    Mayer, M.
    Meijer, H.
    Mertz, S.
    Ohno, S.
    Pagani, O.
    Papadopoulos, E.
    Peccatori, F.
    Penault-Llorca, F.
    Piccart, M. J.
    Pierga, J. Y.
    Rugo, H.
    Shockney, L.
    Sledge, G.
    Swain, S.
    Thomssen, C.
    Tutt, A.
    Vorobiof, D.
    Xu, B.
    Norton, L.
    Winer, E.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (01) : 16 - 33
  • [9] TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
    Carey, Lisa A.
    Rugo, Hope S.
    Marcom, P. Kelly
    Mayer, Erica L.
    Esteva, Francisco J.
    Ma, Cynthia X.
    Liu, Minetta C.
    Storniolo, Anna Maria
    Rimawi, Mothaffar F.
    Forero-Torres, Andres
    Wolff, Antonio C.
    Hobday, Timothy J.
    Ivanova, Anastasia
    Chiu, Wing-Keung
    Ferraro, Madlyn
    Burrows, Emily
    Bernard, Philip S.
    Hoadley, Katherine A.
    Perou, Charles M.
    Winer, Eric P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) : 2615 - 2623
  • [10] Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression
    Cheang, Maggie C. U.
    Martin, Miguel
    Nielsen, Torsten O.
    Prat, Aleix
    Voduc, David
    Rodriguez-Lescure, Alvaro
    Ruiz, Amparo
    Chia, Stephen
    Shepherd, Lois
    Ruiz-Borrego, Manuel
    Calvo, Lourdes
    Alba, Emilio
    Carrasco, Eva
    Caballero, Rosalia
    Tu, Dongsheng
    Pritchard, Kathleen I.
    Levine, Mark N.
    Bramwell, Vivien H.
    Parker, Joel
    Bernard, Philip S.
    Ellis, Matthew J.
    Perou, Charles M.
    Di Leo, Angelo
    Carey, Lisa A.
    [J]. ONCOLOGIST, 2015, 20 (05) : 474 - 482
12345